Q2 2025 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Key Points
- Teva Pharmaceutical Industries Ltd (TEVA) reported its tenth consecutive quarter of growth, with revenues reaching $4.2 billion, driven by its innovative portfolio including AUSTEDO, UZEDY, and AJOVY.
- The company has successfully narrowed its guidance range for AUSTEDO, raising the lower end to $2 billion due to strong performance, particularly in the US market.
- Teva's innovative portfolio is expected to generate between $3.5 billion to $4 billion by 2027, with a long-term target of over $5 billion by 2030.
- The company is on track to achieve $700 million in net savings by 2027 through its modernization program, with 20% of the savings already realized.
- Teva's balance sheet has strengthened, with a reduction in net debt to $15.1 billion and a net debt-to-EBITDA ratio just over 3 times, supported by recent credit rating upgrades.
- Teva's Global Generics business saw a decline of 2%, attributed to strong prior year comparisons and phasing issues, particularly with generic REVLIMID.
- The TAPI segment experienced an 11% decline, described as an anomaly due to seasonality and shipment timing, with expectations for growth over the full year.
- There is uncertainty surrounding the impact of potential US and European tariffs on pharmaceuticals, with Teva still assessing the details and potential mitigation strategies.
- The company faces challenges in expanding UZEDY beyond the long-acting risperidone market into the broader schizophrenia market, despite its strong product profile.
- Teva's guidance indicates that revenue for 2025 may be around or slightly below the midpoint of its range, due to softness in the generics segment and increased competition.
Hello, and welcome to the Teva Pharmaceutical Industries Limited Q2 2025 Earnings Conference Call. My name is Alex. I'll be coordinating the call for today. (Operator Instructions) I'll now hand it over to Chris Stevo, SVP, Investor Relations. Please go ahead.
Thank you, Alex. Good morning and good afternoon, everyone. On this call, we'll be making forward-looking statements, and we disclaim any obligation to update those statements after today's call. If you have more questions about our forward-looking statements, please feel free to see our disclosures under SEC Forms 10-Q and 10-K.
Also during today's call, will be often referring to sales growth in local currency as well as sales growth, excluding the prior year results of our recently divested Japanese business venture. So please bear that in mind. And with that, let me turn it over to Richard.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
